Compare Phenomic AI vs SYNSIGHT
Customers evaluate the quality of Phenomic AI's products using the following success metrics.
Overview
Phenomic AI is 7 yrs old and is based in Canada.
Phenomic AI is a biotechnology company. It develops medicines against the tumor stroma. It offers a platform that interrogates single-cell ribonucleic acid (RNA) data at scale. It uses advanced machine learning tools for processing imaging, ribonucleic acid (RNA) sequencing, and spatial transcriptomics data to understand the biology of single cells sitting in complex multi-cell systems. The company was founded in 2017 and is based in Toronto, Canada.
SYNSIGHT is 11 yrs old and is based in France.
SYNSIGHT is a deep tech company that operates in the pharmaceutical industry, focusing on the discovery and development of drugs targeting RNA. The company's main service involves the development of a screening technology that enables the creation of effective First in Class drug candidates, utilizing a discovery platform that converges artificial intelligence and cell imaging. SYNSIGHT primarily serves the pharmaceutical industry, aiding in the process of drug discovery. It was founded in 2013 and is based in Evry, France.
Demo Video
Leadership
Sam Cooper (Founder)
Guillaume BOLLOT (Founder)
Product
Why Phenomic AI beats SYNSIGHT
Why SYNSIGHT beats Phenomic AI
Benefits
- Progress to Clinic
Products
Tumor stroma discovery platform
Platform for analyzing human tissue data and picking and validating new drug targets against this platform
IGHT PLATFORM
our technological platform is able to design and optimize small molecules therapeutics against RNA, directly from inside the cell. Artificial intelligence, based on our cell screening, is, then, able to design the best compounds.
Customers
Known Partners
Why They Buy
Expert Collections
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Artificial Intelligence
10,958 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.